Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
A patient with obesity, prediabetes, and cardiovascular disease would benefit significantly from semaglutide per the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), which showed 20% reduction in major adverse cardiovascular events in non-diabetic patients treated with semaglutide
Common side effects: Both medications can cause gastrointestinal adverse events like nausea, vomiting, diarrhea, and constipation, especially at the start of treatment
Allowing extra warming time during winter months prevents the discomfort associated with cold solution injection
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications primarily used to manage type 2 diabetes mellitus and, in some formulations, obesity
US$ 28.45
US$ 23.20
US$ 20.25
US$ 24.05
US$ 29.49
US$ 25.84
US$ 20.43
